Anthropic has warned that recursive-self-improving AI could be on the horizon, but the truth is the company is more ...

Recursion (NASDAQ: RXRX) and Exscientia PLC (NASDAQ: EXAI) have announced that their shareholders have overwhelmingly approved the proposed combination between the two companies. The transaction is ...

Anthropic says recursive self-improvement is their chosen path for AI advancing AI. I explain the ins and outs. An AI Insider ...

The maker of Claude wants AI labs, including itself, to prepare for a coordinated slowdown if models begin building their own ...

Transformer Weekly: The Obernolte-Trahan AI Act, Trump’s executive order, and Anthropic discusses a pause ...

Every organism you have ever seen, every ecosystem you have ever walked through, is the ongoing output of an algorithm that ...

Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Unequal access to AI is ...

Abstract: Quaternion-based machine learning algorithms have emerged as a promising candidate for four dimensional (4D) signal processing, which utilize 4D signal dimensions’ correlations for ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals uses AI to develop drugs. The company's goal is to improve and speed up a process that is slow, expensive, and risky. Most medicines that enter the clinic never make it to ...

Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...